Translational oncologic pathology and morpho-molecular biomarkers in neoplasms, with special referen
Pubblicato il 16-08-2026 - Italian Ministry of Education, University and Research in Roma
Organisation/Company Università Campus Bio-Medico di Roma Research Field Medical sciences Researcher Profile Recognised Researcher (R2) Leading Researcher (R4) First Stage Researcher (R1) Established Researcher (R3) Application Deadline 7 Sep 2026
Se i requisiti e l'esperienza richiesti per questo lavoro corrispondono alle sue competenze, la preghiamo di candidarsi tempestivamente.
- 12:00 (UTC) Country Italy Type of Contract Temporary Job Status Full-time Hours Per Week 350 Offer Starting Date 1 Jan 1970 Is the job funded through the EU Research Framework Programme? Not funded by a EU programme Is the Job related to staff position within a Research Infrastructure? NoOffer DescriptionThe programme is placed within oncologic pathology and aims to develop research lines focused on the integrated morphological, immunohistochemical and molecular characterization of neoplasms, with particular attention to tumors of the female genital tract and rare neoplasms or tumors with distinctive diagnostic features.
The research activity will be aimed at:
correlating histological and immunophenotypic patterns with clinico-prognostic data and molecular profiles; identifying and validating diagnostic, prognostic and predictive biomarkers for risk stratification and therapeutic decision-making; applying updated classification and staging systems, including integrated morpho-molecular models; enhancing institutional and multicentre case series through national and international collaborations; generating evidence through clinico-pathological studies, systematic reviews and meta-analyses.
The methodology includes histopathological review of biopsy and surgical specimens, use of targeted immunohistochemical panels, integration with molecular pathology data and clinico-pathological analyses. xysqume
The programme is intended to contribute to precision medicine in oncology by improving diagnostic reproducibility, classification accuracy and the translation of biomarkers into routine pa